The new president of the EOF is the professor of pharmacology of the DTH, Evangelos Manolopoulos – Who are the members of the new board?


By decision of the Minister of Health, Michalis Chrysochoidis, the appointment of the new president of the Organization

By decision of the Minister of Health, Michalis Chrysochoidis, Evangelos Manolopoulos, Professor of Pharmacology at the Medical School of the Democritus University of Thrace, was appointed as President of the National Pharmaceutical Organization (EOF).

The remaining Members of the new Board of Directors of the EOF, according to the announcement of the Ministry of Health, are as follows:

Vice President I, Diomedes Lymberis, Graduate of the Department of Mathematics of the University of Ioannina, holder of a master’s degree in the Organization and Administration of Health Services of the Department of Nursing of the EKPA.

Vice President B’, Spyridon Sapounas, Medical Endocrinologist, with responsibility for issues of scientific research and actions.

Regular Member Maria ConstantiProfessor of Pharmacology at the Medical School of the University of Ioannina with deputy Georgios Papazisi, Professor of pharmacology-Clinical Pharmacology, School of Medicine, AUTH.

Regular Member, George Hamilos, Professor of Microbiology-Infectiology at the Medical School of the University of Crete with Georgios Vassilopoulos as deputy, Professor of Hematology-Molecular Virology at the University of Thessaly Medical School.


Dr. Evangelos Manolopoulos is a Professor of Pharmacology, Pharmacogenomics and Precision Medicine at the Department of Medicine of the Democritus University of Thrace (DPTH) in Alexandroupolis and at the same time offers his services at the University General Hospital of Alexandroupolis.

He received a BS in Biology in 1984 and a PhD in Pharmacology from the Medical School of University of Patras in 1992. He also worked for a year at its Medical School University of Groningen, Netherlands (1989-1990). Between 1992 and 1995 he carried out postdoctoral research at his School of Medicine University of Wisconsin in the USA. He then worked for 3 years (1995-98) at its Medical School Catholic University of Louvain in Belgium.

Since December 1998 Dr. Manolopoulos is a member of the Faculty of Medicine Thrace. He has authored 148 publications, including two in New England Journal of Medicine, which have received a total of more than 4600 references (H factor 36). His current research interests focus on personalized medicine and precision medicine and include basic, translational, and clinical research in pharmacogenomics, epigenetics of drugs used in cardiac disease, anticoagulation, diabetes, oncology, and psychiatric disease.

He has received a total of over 3 million euros in competitive funding for his research. Also, Mr. Manolopoulos is:

– Head of the Unit for Therapeutic Measurement of Drugs and Prohibited Substances University General Hospital of Alexandroupolis (PGNA).

– Director of the Postgraduate Studies Program of the ITH “Clinical Pharmacology and Therapeutics” which has been established in 2006

– Director and Scientific Officer of “Center of Excellence for Pharmacological Studies and Precision Medicine» (IMPReS) of the Ministry of Education and Culture.

– Member of its Board of Directors Hellenic Society of Basic and Clinical Pharmacology (where he has also served as president 2017-2021)

– Member Scientific Council of PGNA (2005 – 2015)

– Member of Ethics and Ethics Committee (Clinical protocol review officer) of PGNA (2007-2015)

– Member Medicines Committee of PGNA (2005-2011)

– Former member of the DOATAP Board of Directors (2020-2022)

– Past president of the European Society for Pharmacogenomics and Personalized Therapy (ESPT) (was president 2020-2022)

– Representative of Greece in European Association of Clinical Pharmacology and Therapeutics (EACPT) continuously for the last 12 years.

Member of the Editorial Board of: British Journal of Clinical Pharmacology, European Journal of Clinical Pharmacology, Pharmacogenomics

– Evaluator of collaborative research proposals submitted to the European Union (2007 – 2022) and to several other Greek and international organizations over the last 20 years.

– During SARS-CoV2 pandemic Dr. Manolopoulos turned his interest to the study of the coronavirus and to monitoring the relevant developments. In fact, he has already published 3 papers on possible ways of early diagnosis and pharmacological treatment of this modern scourge, while throughout the pandemic he fought every day to properly inform the public about vaccines and anti-pandemic drugs through dozens of television and radio interviews and articles in newspapers.

The article is in Greek

Tags: president EOF professor pharmacology DTH Evangelos Manolopoulos members board


NEXT Death, flood defenses and responsibilities today